tiprankstipranks
Travere Therapeutics price target raised to $20 from $18 at Barclays
PremiumThe FlyTravere Therapeutics price target raised to $20 from $18 at Barclays
2M ago
Travere Therapeutics Boosts Sales with FILSPARI Approval
Premium
Company Announcements
Travere Therapeutics Boosts Sales with FILSPARI Approval
2M ago
Travere Therapeutics reports Q3 adjusted EPS (46c), consensus (68c)
Premium
The Fly
Travere Therapeutics reports Q3 adjusted EPS (46c), consensus (68c)
2M ago
Travere reports Swissmedic grants temporary marketing authorization for Filspari
PremiumThe FlyTravere reports Swissmedic grants temporary marketing authorization for Filspari
2M ago
Disney initiated, Cisco upgraded: Wall Street’s top analyst calls
Premium
The Fly
Disney initiated, Cisco upgraded: Wall Street’s top analyst calls
2M ago
Travere Therapeutics initiated with an Outperform at Scotiabank
Premium
The Fly
Travere Therapeutics initiated with an Outperform at Scotiabank
2M ago
Travere Therapeutics price target raised to $18 from $14 at Barclays
PremiumThe FlyTravere Therapeutics price target raised to $18 from $14 at Barclays
3M ago
Travere Therapeutics price target lowered to $22 from $23 at Canaccord
Premium
The Fly
Travere Therapeutics price target lowered to $22 from $23 at Canaccord
3M ago
Travere Therapeutics price target lowered to $17 from $19 at Wedbush
Premium
The Fly
Travere Therapeutics price target lowered to $17 from $19 at Wedbush
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100